Key facts
- It has raised $17.2M across 2 recorded rounds; the latest was Seed Round ($575K) in Oct 2024.
- Notable investors include National Institutes of Health, ExSight Ventures.
- RevOpsis Therapeutics has filed 5 Form Ds with the SEC since 2022, most recently Nov 2024 ($575K sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for RevOpsis Therapeutics
Funding rounds
2 roundsAbout RevOpsis Therapeutics
Operator of a biopharmaceutical company intended to develop innovative treatments for chronic diseases, particularly in ophthalmology. The company's therapy aims at treating retinal diseases like age-related macular degeneration (AMD) by targeting angiogenic factors involved in disease progression using a plug-and-play system to accelerate the design and development of multispecific biologics, enabling doctors to improve the quality of life for patients.
- Sector
- Healthcare
- HQ
- Springfield, IL, United States
- Founded
- 2018
- Employees
- 4
- Website
- revopsis.com/
- Ownership
- Privately Held (backing)
RevOpsis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RevOpsis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RevOpsis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.